Cover Image
市場調查報告書

鼻咽癌:開發中產品分析

Oropharyngeal Cancer - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 213059
出版日期 內容資訊 英文 144 Pages
訂單完成後即時交付
價格
Back to Top
鼻咽癌:開發中產品分析 Oropharyngeal Cancer - Pipeline Review, H2 2016
出版日期: 2016年10月30日 內容資訊: 英文 144 Pages
簡介

鼻咽癌是口咽組織內形成惡性腫瘤的疾病。症狀有聲音嘶啞和改變、難以咀嚼、吞嚥、下巴和舌頭運動困難、慢性口臭、牙齒鬆動和牙痛,疲勞,食慾不振,口內疼痛和出血等。原因有抽煙,大量的酒精攝取,HPV感染,年齡等。

本報告提供鼻咽癌的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢等相關的系統性資訊。

簡介

  • 調查範圍

鼻咽癌概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

鼻咽癌:企業開發中的治療藥

鼻咽癌:大學/機關研究中的治療藥

鼻咽癌:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

鼻咽癌:企業開發中的產品

鼻咽癌:大學/機關研究中的產品

鼻咽癌的治療藥開發企業

  • Advaxis, Inc.
  • AstraZeneca Plc
  • Genticel S.A.
  • Kolltan Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • PNP Therapeutics, Inc.
  • Synta Pharmaceuticals Corp.
  • VLPbio

鼻咽癌:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

鼻咽癌:最近的開發平台趨勢

鼻咽癌:暫停中的計劃

鼻咽癌:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8628IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Oropharyngeal Cancer - Pipeline Review, H2 2016, provides an overview of the Oropharyngeal Cancer (Oncology) pipeline landscape.

Oropharyngeal cancer is a disease which malignant cells form in the tissue of oropharynx. Oropharynx is a middle part of the throat which includes the base of the tongue, the tonsils, the soft palate, and the walls of the pharynx. Oropharyngeal cancers can be divided into two types, HPV-positive, which are related to human papillomavirus infection, and HPV-negative cancers, which are usually linked to alcohol or tobacco use.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Oropharyngeal Cancer - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Oropharyngeal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Oropharyngeal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Oropharyngeal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 5, 5 and 1 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.Oropharyngeal Cancer.

Oropharyngeal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Oropharyngeal Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Oropharyngeal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Oropharyngeal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Oropharyngeal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Oropharyngeal Cancer (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Oropharyngeal Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Oropharyngeal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Oropharyngeal Cancer Overview
  • Therapeutics Development
    • Pipeline Products for Oropharyngeal Cancer - Overview
    • Pipeline Products for Oropharyngeal Cancer - Comparative Analysis
  • Oropharyngeal Cancer - Therapeutics under Development by Companies
  • Oropharyngeal Cancer - Therapeutics under Investigation by Universities/Institutes
  • Oropharyngeal Cancer - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Oropharyngeal Cancer - Products under Development by Companies
  • Oropharyngeal Cancer - Products under Investigation by Universities/Institutes
  • Oropharyngeal Cancer - Companies Involved in Therapeutics Development
    • Advaxis, Inc.
    • AstraZeneca Plc
    • Cell Medica Limited
    • Genticel S.A.
    • Immunovaccine Inc
    • ISA Pharmaceuticals B.V.
    • Kolltan Pharmaceuticals, Inc.
    • Merck & Co., Inc.
    • Novartis AG
    • PNP Therapeutics, Inc.
    • Tessa Therapeutics Pte Ltd
    • VLPbio
  • Oropharyngeal Cancer - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • alpelisib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • axalimogene filolisbac - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy for HPV Associated Cancers - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CMD-004 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DPXE-7 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ganetespib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • gedeptin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GTL-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HNVax - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ISA-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KTN-3379 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nimotuzumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • olaparib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pembrolizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PGV-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TT-12 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target IL-2 and E7 Protein for Cervical Cancer and Oropharyngeal Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Oropharyngeal Cancer - Dormant Projects
  • Oropharyngeal Cancer - Product Development Milestones
    • Featured News & Press Releases
      • Aug 11, 2016: Advaxis Announces that Phase 2 Head and Neck Cancer Study with AXAL Advances to Second Stage
      • Apr 18, 2016: Late Breaking Data at AACR Annual Meeting from Advaxis Phase 2 Study of AXAL Highlights Potential of the Company's Lm Technology™ Platform
      • Sep 14, 2015: FDA Awards Grant for Phase 2 Study of Axalimogene Filolisbac in HPV-Associated Head and Neck Cancer
      • Jun 09, 2015: U.S. FDA approves IND application for TT12 HP-VST to begin Phase I trial involving Adoptive T cell therapy on Oropharyngeal Cancer and Cervical Cancer
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Oropharyngeal Cancer, H2 2016
  • Number of Products under Development for Oropharyngeal Cancer - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Oropharyngeal Cancer - Pipeline by Advaxis, Inc., H2 2016
  • Oropharyngeal Cancer - Pipeline by AstraZeneca Plc, H2 2016
  • Oropharyngeal Cancer - Pipeline by Cell Medica Limited, H2 2016
  • Oropharyngeal Cancer - Pipeline by Genticel S.A., H2 2016
  • Oropharyngeal Cancer - Pipeline by Immunovaccine Inc, H2 2016
  • Oropharyngeal Cancer - Pipeline by ISA Pharmaceuticals B.V., H2 2016
  • Oropharyngeal Cancer - Pipeline by Kolltan Pharmaceuticals, Inc., H2 2016
  • Oropharyngeal Cancer - Pipeline by Merck & Co., Inc., H2 2016
  • Oropharyngeal Cancer - Pipeline by Novartis AG, H2 2016
  • Oropharyngeal Cancer - Pipeline by PNP Therapeutics, Inc., H2 2016
  • Oropharyngeal Cancer - Pipeline by Tessa Therapeutics Pte Ltd, H2 2016
  • Oropharyngeal Cancer - Pipeline by VLPbio, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Oropharyngeal Cancer - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Oropharyngeal Cancer, H2 2016
  • Number of Products under Development for Oropharyngeal Cancer - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top